Document is current
Any future updates will be listed below
-
Authors
Laflör, Lilith Philomena
Siegel, Sonja
Giese, Sabrina
Honegger, Jürgen
Friedel, Anna Lena
Unger, Nicole
van Baal, Lukas
Wrede, Karsten Henning
Kreitschmann-Andermahr, Ilonka
Schock, Lisa https://orcid.org/0009-0009-0615-5752
-
Funding
Funding for this research was provided by:
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 28 November 2025
Accepted: 14 March 2026
First Online: 15 April 2026
Declarations
Conflict of interest: IKA, NU and JH received research support and/or travel grants and/or lecture or advisory board honoraria from Recordati Rare Diseases GmbH Germany, Advanz Pharma GmbH, Pfizer Pharma GmbH Germany, Pfizer Co. and Camurus GmbH, all of which are manufactures of acromegaly medications. SoS received research support and/or travel grants and/or consultation fees from Recordati Rare Diseases, Advanz Pharma GmbH, Pfizer Pharma GmbH Germany and Pfizer Co. ALF, LvB, LL, LS, KHW and SG declare to have no conflict of interest in relation to the content of this article.
Ethics approval: The study had been approved by the ethics boards of the University of Essen (20-9447-BO) and the University of Tübingen. All patients gave written informed consent before participation in the study.
